Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07254286 · ClinicalTrials.gov registry record · Phase 1
Food Effect Study in Healthy Volunteers
A Phase 1 study, sponsored by Biomea Fusion.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07254286: Completed Phase 1 study, sponsored by Biomea Fusion.
NCT07254286 is a Phase 1 study that has completed, run by Biomea Fusion. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07254286, a Phase 1 study, has completed, sponsored by Biomea Fusion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
A phase 1 open-label, randomized, crossover food effect and formulation assessment for icovamenib capsule in healthy volunteers.
Primary Outcome
Tmax
Interventions
- DRUG Icovamenib
- DRUG Icovamenib HPMC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2026-01-14 |
| Phase | Phase 1 |
What the finished NCT07254286 record still lists
NCT07254286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Icovamenib is the first listed.
NCT07254286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07254286 about?
NCT07254286 is a clinical study titled "Food Effect Study in Healthy Volunteers". A phase 1 open-label, randomized, crossover food effect and formulation assessment for icovamenib capsule in healthy volunteers.
What is the current status of trial NCT07254286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-09-11. Estimated completion is 2026-01-14.
What interventions are being tested in trial NCT07254286?
The interventions under investigation include: Icovamenib (DRUG), Icovamenib HPMC (DRUG).
Who is sponsoring clinical trial NCT07254286?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07254286's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI